PMID- 25424627
OWN - NLM
STAT- MEDLINE
DCOM- 20151006
LR  - 20221207
IS  - 1477-7525 (Electronic)
IS  - 1477-7525 (Linking)
VI  - 12
DP  - 2014 Nov 26
TI  - Improvements in quality of life associated with biphasic insulin aspart 30 in 
      type 2 diabetes patients in China: results from the A1chieve(R) observational 
      study.
PG  - 137
LID - 10.1186/s12955-014-0137-9 [doi]
LID - 137
AB  - BACKGROUND: Based on the 24-week, prospective, non-interventional, observational 
      study, A1chieve(R), we investigated how health-related quality of life (HRQoL) 
      changed, and the predictors of such changes, in Chinese people with type 2 
      diabetes mellitus (T2DM) after starting with, or switching to, biphasic insulin 
      aspart 30 (BIAsp 30). METHODS: In total, 8,578 people with T2DM starting 
      treatment with, or switching to, BIAsp 30 were recruited from 130 urban hospitals 
      in China. HRQoL was assessed at baseline and 24 weeks using the EuroQol-5 
      dimensions (EQ-5D) questionnaire. Descriptive statistics, paired t-test, and 
      chi-square test were conducted and the linear ordinary least squares regression 
      model was used to determine predictors for changes in EQ-5D score. RESULTS: 
      Haemoglobin A1c (HbA1c) decreased from 9.5% to 7.0% after 24 weeks. The reported 
      HRQoL measured by the EQ-5D visual analogue scale score increased by 6.2 
      (p < 0.001) from 75.8 to 82.0, and EQ-5D index score increased by 0.018 
      (p < 0.001) from 0.875 to 0.893 for the cohort over 24 weeks. The percentage of 
      patients reporting no problems in the mobility, pain/discomfort, and 
      anxiety/depression dimensions of EQ-5D increased significantly (p < 0.001) from 
      88.4% to 91.4%, 77.3% to 82.8%, and 74.2% to 77.1%, respectively. Patients with 
      higher HbA1c levels at baseline, major hypoglycaemia or micro-complications 
      exhibited significantly larger changes in EQ-5D scores than those with lower 
      baseline HbA1c levels, without major hypoglycaemia or micro-complications after 
      controlling for demographics and other baseline characteristics. CONCLUSIONS: 
      BIAsp 30 treatment was associated with improved glycaemic control and HRQoL in 
      T2DM patients in China. Patients with worse health conditions were more likely to 
      experience larger improvements in HRQoL than those with better health conditions. 
      TRIAL REGISTRATION: ClinicalTrials.gov, NCT00869908 .
FAU - Yang, Wenying
AU  - Yang W
AD  - China-Japan Friendship Hospital, Beijing, China. ywying_1010@163.com.
FAU - Zhuang, Xiaoming
AU  - Zhuang X
AD  - Fu Xing Hospital, Capital Medical University, Beijing, China. 
      zhuangxiaoming@yahoo.com.cn.
FAU - Li, Yukun
AU  - Li Y
AD  - The Third Hospital of Hebei Medical University, Hebei, China. 
      liyukun@medmail.com.cn.
FAU - Wang, Qing
AU  - Wang Q
AD  - Department of Endocrinology, China-Japan Union Hospital of Jilin University, 
      Changchun, China. manu_pub@163.com.
FAU - Bian, Rongwen
AU  - Bian R
AD  - Jiangsu Provincial Official Hospital, Jiangsu, China. bianrw@126.com.
FAU - Shen, Jianguo
AU  - Shen J
AD  - The First Affiliated Hospital, Zhejiang University, Zhejiang, China. 
      jgshen@medmail.com.cn.
FAU - Hammerby, Eva
AU  - Hammerby E
AD  - Novo NordiskA/S, Copenhagen, Denmark. ehby@nvonordisk.com.
FAU - Yang, Li
AU  - Yang L
AD  - Department of Health Policy and Management, School of Public Health, Peking 
      University, No 38 Xueyuan Rd. Haidian District, Beijing, 100191, China. 
      lyang@hsc.pku.edu.cn.
LA  - eng
SI  - ClinicalTrials.gov/NCT00869908
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20141126
PL  - England
TA  - Health Qual Life Outcomes
JT  - Health and quality of life outcomes
JID - 101153626
RN  - 0 (Biphasic Insulins)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (insulin aspart, insulin aspart protamine drug combination 30:70)
RN  - 53027-39-7 (Insulin, Isophane)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biphasic Insulins/*therapeutic use
MH  - China
MH  - Diabetes Mellitus, Type 2/drug therapy/*psychology
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Aspart/*therapeutic use
MH  - Insulin, Isophane/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Quality of Life
MH  - *Surveys and Questionnaires
MH  - Treatment Outcome
PMC - PMC4253979
EDAT- 2014/11/27 06:00
MHDA- 2015/10/07 06:00
PMCR- 2014/11/26
CRDT- 2014/11/27 06:00
PHST- 2013/12/22 00:00 [received]
PHST- 2014/08/21 00:00 [accepted]
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2015/10/07 06:00 [medline]
PHST- 2014/11/26 00:00 [pmc-release]
AID - s12955-014-0137-9 [pii]
AID - 137 [pii]
AID - 10.1186/s12955-014-0137-9 [doi]
PST - epublish
SO  - Health Qual Life Outcomes. 2014 Nov 26;12:137. doi: 10.1186/s12955-014-0137-9.